Pfizer (PFE) on Wednesday announced early positive results for the first phase of its coronavirus vaccine trial, sparking hopes that an effective treatment can help turn the tide amid an implacable surge in new infections....
If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Dupont De Nemours Inc. (NYSE:DD) stock. In its Q4 2019 investor letter – you can download a copy here – the […]...
The COVID-19 pandemic has decimated the U.S. economy, yet the stock market is alive and well. Against the backdrop of a recession, the market actually had its strongest quarter in over 20 years, with the S&P 500 notching its largest quarterly gain since the last quarter of 1998, surging 20%. As for the NASDAQ, it climbed 31% higher during the quarter, marking its best quarterly performance since Q4 1999.While certainly volatile, the quarter saw investors take an optimistic approach due to reopening efforts and unprecedented stimulus packages. That being said, going forward into Q3, plenty of uncertainty is lingering over Wall Street. So, how are investors supposed to lock in on compelling plays? The Street’s pros can provide some much-needed inspiration, namely those from investment firm Goldman Sachs.Taking all of this into consideration, we used TipRanks’ database to learn more about three stocks backed by Goldman Sachs. As it turns out,...
If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on 3M Company (NYSE:MMM) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […]...
(Bloomberg) -- An early trial of an experimental coronavirus vaccine from Pfizer Inc. and BioNtech SE showed it’s safe and prompted patients to produce antibodies against the new virus, keeping it in the lead pack for a pandemic shot.The messenger RNA product was tested on 45 healthy adults divided in several groups: 24 of them got two injections with two different doses of the experimental vaccine, 12 of them received a single shot with a very high dose and nine patients got two dummy injections. The two-shot groups produced the highest level of antibodies.Pfizer and Germany’s BioNTech are in a race with companies including AstraZeneca Plc, Moderna Inc. and dozens of other biopharmaceutical outfits and academic groups to come up with a safe and effective vaccine against Covid-19. With almost 10.5 million confirmed cases around the globe and over half a million deaths, drugmakers are under increasing pressure to deliver.“I see...
